Dyne Therapeutics (NASDAQ:DYN) Trading Down 7.1% – Time to Sell?

Dyne Therapeutics, Inc. (NASDAQ:DYN) shares traded down 7.1% on Friday . The stock traded as low as $27.80 and last traded at $28.16. 245,371 shares changed hands during mid-day trading, a decline of 84% from the average session volume of 1,489,411 shares. The stock had previously closed at $30.31.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on DYN. StockNews.com cut shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. Piper Sandler reaffirmed an “overweight” rating and issued a $53.00 price target on shares of Dyne Therapeutics in a research note on Monday, September 23rd. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research note on Wednesday. Stifel Nicolaus lifted their price target on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $51.40.

Dyne Therapeutics Trading Down 5.4 %

The firm has a market cap of $2.92 billion, a price-to-earnings ratio of -7.89 and a beta of 1.10. The business’s 50-day simple moving average is $32.58 and its two-hundred day simple moving average is $35.08.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.25). On average, analysts forecast that Dyne Therapeutics, Inc. will post -3.02 earnings per share for the current fiscal year.

Insider Activity at Dyne Therapeutics

In related news, CEO John Cox acquired 32,000 shares of the company’s stock in a transaction on Wednesday, September 4th. The shares were acquired at an average cost of $33.04 per share, for a total transaction of $1,057,280.00. Following the purchase, the chief executive officer now owns 8,000 shares in the company, valued at approximately $264,320. The trade was a -133.33 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Susanna Gatti High sold 8,976 shares of the firm’s stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $34.41, for a total value of $308,864.16. Following the transaction, the chief operating officer now owns 131,636 shares in the company, valued at approximately $4,529,594.76. This trade represents a 6.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 158,975 shares of company stock valued at $5,693,789. 20.77% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC grew its holdings in shares of Dyne Therapeutics by 904.1% during the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after purchasing an additional 669 shares in the last quarter. Quantbot Technologies LP bought a new stake in Dyne Therapeutics in the 3rd quarter worth approximately $34,000. Point72 DIFC Ltd bought a new stake in Dyne Therapeutics in the 3rd quarter worth approximately $36,000. US Bancorp DE lifted its position in Dyne Therapeutics by 776.9% in the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after buying an additional 1,212 shares during the last quarter. Finally, Values First Advisors Inc. bought a new stake in Dyne Therapeutics in the 3rd quarter worth approximately $62,000. Hedge funds and other institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.